Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
OCUL 11.06.2024
Date of Upcoming Event:2024-11-14
Name of Upcoming Event:Conference call and webcast
About Gravity Analytica
Conference call and webcast to begin at 8:00 AM ET
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
Conference Call and Webcast Information:
Date: Thursday, November 14, 2024, at 8:00 AM ET
Participant Dial-In (U.S.): 1 (877) 407-9039
Participant Dial-in (International): 1 (201) 689-8470
Webcast Access: Please clickhere
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
AboutOcularTherapeutix,Inc.Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLITM (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYXTM proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVATM (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA®are registered trademarks of Ocular Therapeutix, Inc. AXPAXLITM, PAXTRAVATM, ELUTYXTM, and Ocular TherapeutixTM are trademarks of Ocular Therapeutix, Inc.
Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com
